ANMAT Guide
ANMAT regulatory translation requirements.
A technical guide to the linguistic, certification, and dossier rules Argentina's Administración Nacional de Medicamentos, Alimentos y Tecnología Médica applies to clinical trial translation under Disposición 6677/10 — and why general-purpose machine translation creates avoidable observaciones in first-cycle review.
Published July 2026
The context
Argentina reviews in Spanish, and does it under a codified GCP regime.
ANMAT is the national authority for medicines, biologics, medical devices, and clinical research in Argentina. Since 2010, pharmacological clinical research on humans has been governed by Disposición 6677/10, which sets the Good Clinical Practice regime the agency applies to trial authorization, informed consent, investigator conduct, sponsor obligations, safety reporting, and the linguistic form of every document that enters the dossier.
Every clinical trial authorization, protocol amendment, and sanitary registration is reviewed in Spanish. Source documents in English or another language are accepted only with a translation that meets Argentina's formal requirements. Anything less generates an observación, and each round of clarifications resets the review clock. Sponsors that treat Argentina as an interchangeable Spanish market — using Peninsular, Mexican, or neutral Latin-American register — collect avoidable queries on the informed consent alone.
Disposición 6677/10
What the GCP regime actually requires of your documents.
Disposición 6677/10 defines the content and form of the pharmacological clinical research dossier. For translation purposes, its practical implications are consistent: the protocol, its amendments, the investigator's brochure, the informed consent form for each site, investigator CVs, financial disclosures, case report forms, SUSAR narratives, monitoring plans, and the study insurance certificate must all be presented in Spanish that a Buenos Aires reviewer can read without ambiguity.
The informed consent is the most sensitive document in the file. Article-level review compares the Spanish ICF against the protocol's inclusion/exclusion criteria, risks, and procedures. Discrepancies between the ICF and the protocol — a risk that appears in one document and not the other, a procedure described with different terminology — are treated as substantive, not stylistic, and delay the authorization until the sponsor reconciles both versions.
Safety reporting under 6677/10 is time-bound. SUSAR narratives and periodic safety reports must be delivered in Spanish within the deadlines the disposition sets. A translation bottleneck at the safety desk is a compliance problem, not a language problem.
What must be translated
The documents that move an Argentina dossier.
For a clinical trial authorization under 6677/10, ANMAT expects Spanish translations of the protocol and all amendments, the investigator's brochure, the site-specific informed consent forms, investigator CVs and financial disclosures, case report forms, SUSAR/SAE narratives, the monitoring plan, and the study insurance certificate. Device trials add instructions for use, risk analysis, and biocompatibility summaries. For sanitary registration, the list expands to include labeling, CMC sections, stability data, GMP certificates, and Certificates of Pharmaceutical Product (CPP).
Each document must be complete. Partial translations, body text without appendices, or omitted footnotes and table headers are treated as incomplete submissions. ANMAT reviewers compare the Spanish translation against the source line by line in disputed areas, so the two versions must match exactly in structure, section numbering, and cross-references.
Certification and traductor público
ANMAT expects more than a bilingual page.
Argentina applies a two-track certification model. Clinical documents — protocol, IB, ICF, CRF, SUSAR narratives — must be delivered in Spanish that preserves clinical, statistical, and regulatory intent, and the sponsor is accountable for that accuracy. Foreign-language legal instruments — powers of attorney, corporate resolutions, GMP certificates, CPPs, insurance policies — must be translated by a traductor público matriculado, a sworn public translator registered with the Colegio de Traductores Públicos of the relevant jurisdiction (in Buenos Aires, the CTPCBA), with signature legalized where required.
Foreign public documents used as legal instruments generally require an apostille under the Hague Convention (Argentina is a signatory) before they can be presented to ANMAT, together with a Spanish public translation. The safest default is: apostille every foreign public document, route every legal instrument through a traductor público, and hold every clinical document to the same evidentiary bar even where a public translation is not strictly compulsory.
Where translations fail
The five most common sources of ANMAT observaciones.
- Wrong Spanish register in the informed consent. ANMAT reviews consent forms for readability in rioplatense Spanish. Peninsular or neutral Latin-American register is flagged as unsuitable for the population the trial actually enrolls.
- Protocol / ICF discrepancies. Any risk, procedure, or eligibility criterion that appears in the protocol but is missing, reworded, or softened in the ICF is a substantive observation, not a stylistic one.
- Missing apostilles or traductor público sign-off. Powers of attorney, GMP certificates, CPPs, and insurance certificates submitted without a valid apostille or without a sworn public translation are rejected on a paperwork basis, regardless of translation quality.
- Inconsistent drug or device nomenclature. If a product is referred to by three different names across the protocol, ICF, and IFU, ANMAT will ask for a harmonized version. Controlled vocabulary is not optional under 6677/10.
- Untranslated appendices, footnotes, or table headers. Reviewers treat partial translations as incomplete dossiers, not as minor omissions. Time lost is identical to a substantive query.
How we cover this
The First-Pass Acceptance Program for Argentina.
Our clinical trial translation service pairs private-inference translation with medical review by clinicians who understand rioplatense regulatory Spanish and the specific expectations of 6677/10, then routes legal instruments to matriculated traductores públicos in Buenos Aires and coordinates apostille handling before the dossier is assembled. The output is a Spanish submission package aligned to ANMAT's expectations — not a generic translation.
We back it with a written SLA: zero critical errors on delivery, or we re-issue at no cost and credit $2,500 per business day of delay (Tier 1-A). For ANMAT submissions, that credit is priced against the actual cost of a delayed clinical trial authorization or a late sanitary registration.
What "specialized" actually means
Clinical trial translation services are a regulatory discipline, not a language service.
A specialized workflow pairs machine-assisted translation with medical review by clinicians who read local regulatory guidance for a living. The platform compresses time. The medical reviewer preserves clinical and regulatory intent. Neither one alone is a substitute for the other, and the Argentina-market outcome depends on both being present.
For a deeper look at where general-purpose AI translation falls short in Phase III documentation, read our comparison of AI vs. medical review accuracy.
Related resources
Continue reading across the LatAm regulatory stack.
Clinical Trial Translation Services hub
The Amavita overview of LatAm regulator coverage, MD-led review, and the First-Pass Acceptance SLA.
Read more →INVIMA translation requirements (Colombia)
Colombian Spanish submission rules, certified translator requirements, and common auto de requerimiento.
Read more →COFEPRIS translation requirements (Mexico)
Mexican Spanish submission rules, perito traductor requirements, and common requerimientos.
Read more →ANVISA translation requirements (Brazil)
Portuguese submission rules, tradutor público juramentado requirements, and common exigências.
Read more →Ready to move an Argentina program? Start an ANMAT pilot with Amavita →
Next step
Move an Argentina program through the workflow.
Tell us about an ANMAT submission or Argentina clinical trial on your calendar. Our team will reach out within 2 business days with a scoped pilot proposal.